Literature DB >> 12584229

Heterozygous recipient and donor HFE mutations associated with a hereditary haemochromatosis phenotype after liver transplantation.

A J Wigg1, H Harley, G Casey.   

Abstract

We observed the development of phenotypic hereditary haemochromatosis in a non-hereditary haemochromatosis liver transplant recipient, following transplantation with a liver from a C282Y heterozygous donor. No cause for secondary iron overload was identified. Subsequent sequencing of the HFE gene of both donor and recipient revealed a strong candidate for a novel pathogenic HFE mutation. In the recipient, heterozygosity for a single base substitution in exon 1, g.18 G>C, resulting in the substitution of arginine by serine at codon 6 (R6S), was detected. This R6S variation is likely to represent a novel pathogenic missense mutation of the HFE gene. An interaction between R6S heterozygosity in the recipient and C282Y heterozygosity in the donor liver is the most likely explanation for the development of iron overload in this patient. The report suggests that an hepatic defect is required for expression of hereditary haemochromatosis and that the intestinal HFE genotype is not the exclusive determinant of iron status. It also raises the possibility that a hereditary haemochromatosis phenotype may result from transplantation of C282Y heterozygous donor livers into recipients with heterozygous pathogenic HFE mutations. This possibility may have significant implications for the common practice of transplanting C282Y heterozygous livers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584229      PMCID: PMC1773567          DOI: 10.1136/gut.52.3.433

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  Transplantation of haemochromatosis liver and intestine into a normal recipient.

Authors:  P C Adams; G Jeffrey; K Alanen; S Chakrabarti; R Preshaw; W Howson; D Grant
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

2.  Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis.

Authors:  A Piperno; C Arosio; L Fossati; M Viganò; P Trombini; A Vergani; G Mancia
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

3.  A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.

Authors:  O T Njajou; N Vaessen; M Joosse; B Berghuis; J W van Dongen; M H Breuning; P J Snijders; W P Rutten; L A Sandkuijl; B A Oostra; C M van Duijn; P Heutink
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

4.  Uncommon mutations and polymorphisms in the hemochromatosis gene.

Authors:  J J Pointon; D Wallace; A T Merryweather-Clarke; K J Robson
Journal:  Genet Test       Date:  2000

5.  A homozygous HFE gene splice site mutation (IVS5+1 G/A) in a hereditary hemochromatosis patient of Vietnamese origin.

Authors:  Michael Steiner; Kenneth Ocran; Janine Genschel; Patrick Meier; Helga Gerl; Michael Ventz; Marie-Luise Schneider; Carsten Büttner; Kamilla Wadowska; Wolfgang Kerner; Peter Schuff-Werner; Herbert Lochs; Hartmut Schmidt
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

6.  Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3).

Authors:  Vinod Devalia; Kymberley Carter; Ann P Walker; Stephen J Perkins; Mark Worwood; Alison May; James S Dooley
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

7.  Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis.

Authors:  Daniel F Wallace; Palle Pedersen; Jeannette L Dixon; Peter Stephenson; Jeffrey W Searle; Lawrie W Powell; V Nathan Subramaniam
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.

Authors:  G Montosi; A Donovan; A Totaro; C Garuti; E Pignatti; S Cassanelli; C C Trenor; P Gasparini; N C Andrews; A Pietrangelo
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

9.  Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene.

Authors:  Domenico Girelli; Claudia Bozzini; Antonella Roetto; Federica Alberti; Filomena Daraio; Romano Colombari; Oliviero Olivieri; Roberto Corrocher; Clara Camaschella
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

10.  Exclusion of ZIRTL as candidate gene of juvenile hemochromatosis and refinement of the critical interval on 1q21.

Authors:  A Roetto; F Alberti; F Daraio; A Cali; M Cazzola; A Totaro; P Gasparini; C Camaschella
Journal:  Blood Cells Mol Dis       Date:  2000-06       Impact factor: 3.039

View more
  6 in total

1.  Lessons from liver transplantation: flip, flop, and why?

Authors:  P C Adams
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

2.  The Q283P amino-acid change in HFE leads to structural and functional consequences similar to those described for the mutated 282Y HFE protein.

Authors:  Chandran Ka; Gérald Le Gac; Francois-Yves Dupradeau; Jacques Rochette; Claude Férec
Journal:  Hum Genet       Date:  2005-06-18       Impact factor: 4.132

3.  Function of the hemochromatosis protein HFE: Lessons from animal models.

Authors:  Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

Review 4.  Recent advances in understanding haemochromatosis: a transition state.

Authors:  K J H Robson; A T Merryweather-Clarke; E Cadet; V Viprakasit; M G Zaahl; J J Pointon; D J Weatherall; J Rochette
Journal:  J Med Genet       Date:  2004-10       Impact factor: 6.318

5.  Hepatic Iron Overload following Liver Transplantation from a C282Y/H63D Compound Heterozygous Donor.

Authors:  E Veitsman; E Pras; O Pappo; A Arish; R Eshkenazi; C Feray; J Calderaro; D Azoulay; Z Ben Ari
Journal:  Case Reports Hepatol       Date:  2018-05-31

Review 6.  Molecular basis of HFE-hemochromatosis.

Authors:  Maja Vujić
Journal:  Front Pharmacol       Date:  2014-03-11       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.